Skip to main content

Featured

Canadian Money Brief: 5 Things to Know Today — Tuesday, May 19, 2026

  From Canada's surprise rise to near the top of G7 growth charts, to softening rents, a cooling job market, and a looming trade renegotiation with the U.S. — here's what's moving your money today. 1 Economy & Growth Canada Is the 2nd-Fastest Growing G7 Economy — But Headwinds Loom The IMF now projects Canada to post the 2nd-fastest GDP growth in the G7 for 2026–2027, and the Spring 2026 Economic Update backs that up: the economy grew 1.7% in 2025 while avoiding a recession. Business investment is rebounding — up 2.6% in Q4 2025 — and Canada has attracted a record $97 billion in foreign direct investment. The engine? A relative tariff advantage under CUSMA, strong energy exports, and targeted federal spending. The caution: that momentum is fragile. Higher oil prices, a soft labour market, and a critical U.S. trade review mid-year could all shift the outlook quickly. 💡 What it means for you A growing economy generally supports job stability and wage gains — but don...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment